Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CAPN1 | P07384 | 1/20 | 0.33 |
| ▸ | BCHE | P06276 | 1/20 | 0.33 |
| ▸ | ACHE | P22303 | 1/20 | 0.33 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.31 |
| ▸ | PLK1 | P53350 | 2/20 | 0.31 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.31 |
| ▸ | CCKBR | P32239 | 1/20 | 0.31 |
| ▸ | CTSS | P25774 | 1/20 | 0.30 |
| ▸ | CTSK | P43235 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19505993 | 0.91 | CAPN1 (0.33) | CAPN1BCHEACHEGLO1PLK1 | |
| SCHEMBL19450704 | 0.89 | CAPN1 (0.37) | CAPN1BCHEACHEGLO1PLK1 | |
| SCHEMBL22373639 | 0.85 | CAPN1 (0.38) | CAPN1BCHEACHEGLO1PLK1 | |
| SCHEMBL30019872 | 0.77 | NOD1 (0.47) | CAPN1NOD1 | |
| SCHEMBL24235778 | 0.77 | GLP1R (0.43) | CAPN1NOD1 | |
| SCHEMBL30019912 | 0.76 | NOD1 (0.47) | CAPN1NOD1 | |
| SCHEMBL20998108 | 0.76 | CTSK (0.41) | CAPN1GLO1PLK1NOD1CTSS | |
| SCHEMBL19506154 | 0.75 | CTSS (0.37) | CAPN1GLO1PLK1NOD1CTSS | |
| SCHEMBL24235602 | 0.73 | GLO1 (0.42) | CAPN1GLO1NOD1CTSSCTSK | |
| SCHEMBL25977092 | 0.73 | TSHR (0.40) | CAPN1BCHEACHECCKBR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11485792-B2 | Antibodies, uses thereof and conjugates thereof | POLYTHERICS LIMITED | 2022-11-01 | — | — | US | disclosed |
| US-20190144562-A1 | ANTIBODIES, USES THEREOF AND CONJUGATES THEREOF | ABZENA (UK) LIMITED (GB) | 2019-05-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190144562-A1 | ANTIBODIES, USES THEREOF AND CONJUGATES THEREOF | KLK3, VSIG8, IGLV6-57 | CAPN1 4587/4885BCHE 1359/4885ACHE 3422/4885 |
| US-11485792-B2 | Antibodies, uses thereof and conjugates thereof | KLK3, VSIG8, IGLV6-57 | CAPN1 4587/4885BCHE 1359/4885ACHE 3422/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.